Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6070 plus ifinatamab deruxtecan in relapsed/refractory extensive-stage small cell lung cancer
jRCT2031250039Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of gocatamig and ifinatamab deruxtecan in small cell lung cancer (SCLC), sponsored by Merck & Co. Primary endpoints: Adverse events, Dose limiting toxicities and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
gocatamigifinatamab deruxtecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2031250039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250039.